Kanadani TCM, et al. - Authors evaluated the subfoveal choroidal thickness (SFChT) and the impact of treatment with anti-vascular endothelial growth factor (anti-VEGF) agents on the SFChT in age-related macular degeneration (AMD). As per data, in eyes with polypoidal choroidal vasculopathy (PCV), SFChT was greatest and it was least in eyes with retinal angiomatous proliferation (RAP). After treatment, greater reduction in SFChT was seen in the RAP cases. Findings suggested no association of the decrease in SFChT after 12 months of anti-VEGF treatment with the number of injections and in all AMD subtypes, there was no correlation between the baseline SFChT and visual acuity.